PsycEXTRA Dataset 1996
DOI: 10.1037/e413522005-010
|View full text |Cite
|
Sign up to set email alerts
|

Membership committee report

Abstract: This year we had 24 new members (5 of which were vendors) and contacted all of the individual members multiple times throughout the year. The goal was to ensure new members felt engaged and able to ask questions at any time. Each member of the committee was assigned 2 new members to keep up with during the year. Any bibliographies new members agreed to publish were distributed to the Express. Committee members contacted their new members to determine if they would like to be recognized at the MCMLA Virtual 201… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…One advantage of phage therapy is the large application without disruptions to the gut microbiota . A vast abundance of the phages in nature also ensures a nearly endless pipeline enabling application as “cocktails”, thereby reducing the chances of resistance developing to an individual treatment. Some recent clinical studies including treatment of Staphylococcus aureus in prosthesis infections, Mycobacterium abscessus , Burkholderia dolosa , and Achromobacter xylosoxidans in lung transplants, Acinetobacter baumannii in pneumonia, and Klebsiella pneumoniae in fracture-related infections . Phase II clinical trials have also been undertaken, including the European Phage Therapy Unit (PTU) between 2008 and 2010 reporting full recovery or clinical improvement in 40% of patients (157 total), treatment of leg ulcer pathogens using Intralytix phage cocktail WPP-201 (targeting E. coli , S. aureus , and Pseudomonas aeruginosa ), which reported no side effects, and some currently ongoing clinical trials .…”
Section: Introductionmentioning
confidence: 99%
“…One advantage of phage therapy is the large application without disruptions to the gut microbiota . A vast abundance of the phages in nature also ensures a nearly endless pipeline enabling application as “cocktails”, thereby reducing the chances of resistance developing to an individual treatment. Some recent clinical studies including treatment of Staphylococcus aureus in prosthesis infections, Mycobacterium abscessus , Burkholderia dolosa , and Achromobacter xylosoxidans in lung transplants, Acinetobacter baumannii in pneumonia, and Klebsiella pneumoniae in fracture-related infections . Phase II clinical trials have also been undertaken, including the European Phage Therapy Unit (PTU) between 2008 and 2010 reporting full recovery or clinical improvement in 40% of patients (157 total), treatment of leg ulcer pathogens using Intralytix phage cocktail WPP-201 (targeting E. coli , S. aureus , and Pseudomonas aeruginosa ), which reported no side effects, and some currently ongoing clinical trials .…”
Section: Introductionmentioning
confidence: 99%